Patient
SITE002-0062
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE002 (USA) (Dr. Nolan)
consented 2025-11-09
Adverse events
9
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 9
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-16 (study day 116); relationship: RELATED
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-13 (study day 113); relationship: RELATED
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-08-21 (study day 90); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-21 (study day 59); relationship: NOT RELATED
Grade 2 Rash — outcome: RECOVERED/RESOLVED; onset 2022-07-07 (study day 45); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 36); relationship: RELATED
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-22 (study day 30); relationship: NOT RELATED
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-06-22 (study day 30); relationship: not assessed; serious criteria: life-threatening
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-02 (study day 10); relationship: RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.